Board Meeting Details

The Board of Directors meeting was held on October 28, 2026, commencing at 5:00 p.m. and concluding at 6:00 p.m. The meeting was conducted to approve the financial results.

Financial Results Overview

The company reported both standalone and consolidated financial results for Q2 FY2026 (quarter ended September 30, 2026) and H1 FY2026 (half year ended September 30, 2026).

Standalone Financial Performance (₹ in Lakhs)

Quarter Ended September 30, 2026:

  • Revenue from operations: ₹45,300.95
  • Other income: ₹528.08
  • Total income: ₹45,829.03
  • Profit before tax: ₹7,883.03
  • Tax expense: ₹2,064.52
  • Profit for the period: ₹5,828.51
  • Basic EPS: ₹13.35 (not annualized)

Half Year Ended September 30, 2026:

  • Revenue from operations: ₹73,702.85
  • Other income: ₹2,203.79
  • Total income: ₹75,906.64
  • Profit before tax: ₹12,722.59
  • Tax expense: ₹3,299.61
  • Profit for the period: ₹9,422.98
  • Basic EPS: ₹21.59 (not annualized)

Consolidated Financial Performance (₹ in Lakhs)

Quarter Ended September 30, 2026:

  • Revenue from operations: ₹45,570.28
  • Other income: ₹398.87
  • Total income: ₹45,969.15
  • Profit before tax: ₹7,563.67
  • Tax expense: ₹1,988.98
  • Profit for the period: ₹5,574.69
  • Profit attributable to owners: ₹5,550.31
  • Basic EPS: ₹12.81 (not annualized)

Half Year Ended September 30, 2026:

  • Revenue from operations: ₹74,212.10
  • Other income: ₹1,950.94
  • Total income: ₹76,163.04
  • Profit before tax: ₹12,173.48
  • Tax expense: ₹3,207.70
  • Profit for the period: ₹8,965.79
  • Profit attributable to owners: ₹9,007.40
  • Basic EPS: ₹20.64 (not annualized)

Segment-wise Performance

The company operates in four reportable segments:

1. Chemicals (Organic and Inorganic)

2. Solar Power (Generation and Distribution)

3. Pharma

4. Others

Standalone Segment Revenue Q2 FY2026:

  • Chemicals: ₹44,668.23
  • Solar Power: ₹536.54
  • Pharma: ₹8.32
  • Others: ₹87.87 (inter-segment revenue deducted)

Consolidated Segment Revenue Q2 FY2026:

  • Chemicals: ₹44,668.23
  • Solar Power: ₹807.48
  • Pharma: ₹6.70
  • Others: ₹87.87 (inter-segment revenue deducted)

Assets and Liabilities Position

Standalone as of September 30, 2026:

  • Total assets: ₹92,245.72
  • Total equity: ₹68,348.13
  • Total liabilities: ₹23,897.59

Consolidated as of September 30, 2026:

  • Total assets: ₹1,02,950.62
  • Total equity: ₹67,216.28
  • Total liabilities: ₹35,734.34

Cash Flow Statements

Standalone H1 FY2026:

  • Cash from operating activities: ₹5,254.17
  • Cash used in investing activities: ₹(4,179.68)
  • Cash from financing activities: ₹(1,078.96)
  • Net decrease in cash: ₹(13.04)

Consolidated H1 FY2026:

  • Cash from operating activities: ₹5,241.80
  • Cash used in investing activities: ₹(8,329.79)
  • Cash from financing activities: ₹3,044.15
  • Net decrease in cash: ₹(52.41)

Auditor Review

The unaudited financial results were subject to limited review by the statutory auditors, M/s Sarda & Pareek LLP, Chartered Accountants. The auditors issued a review report stating that the results give a true and fair view in accordance with the applicable accounting standards and SEBI regulations.

Subsidiaries Included in Consolidation

The consolidated results include the following subsidiaries:

1. Bhageria & Jajodia Pharmaceuticals Private Limited

2. Bhageria Rare Earth Minerals Private Limited

3. Hikaru Solar Power Private Limited

4. New Ahilyanagar Solar Private Limited

5. Rahuri Cleantech Private Limited

6. Salasar Renewables Private Limited

Additional Information

The full financial results are available on the company's website (www.bhageriagroup.com) and stock exchange websites (www.nseindia.com and www.bseindia.com).